Patents Examined by Nancy A. Johnson
-
Patent number: 5696237Abstract: The present invention describes recombinant antibody toxin fusion proteins which selectively kill cells bearing appropriate antigens or receptors.Type: GrantFiled: June 5, 1995Date of Patent: December 9, 1997Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: David FitzGerald, Vijay Kumar Chaudhary, Ira Harry Pastan, Thomas Alexander Waldmann, Cary L. Queen
-
Patent number: 5695760Abstract: Methods for preventing or treating inflammation are provided. Specifically, such inflammation can be effectively treated or prevented through the use of anti-ICAM-1 antibodies which have been modified to contain poly(ethylene) glycol adducts. The modification reduces the immunoreactivity of the antibodies, and thus increases the antibodies' serum half life. Methods for forming, purifying and using such modified antibodies are described.Type: GrantFiled: April 24, 1995Date of Patent: December 9, 1997Assignee: Boehringer Inglehiem Pharmaceuticals, Inc.Inventors: Ronald Bertrand Faanes, Paul Edward McGoff, Bret Allen Shirley, David Stuart Scher
-
Patent number: 5693758Abstract: A polypeptide competitor or analogue for human Immunoglobulin E (IgE) low affinity sites comprises a polypeptide which has a sequence of amino acid which has a sequence of amino acids which is shown in Table I. This amino acid sequence corresponds to amino acids 340 to 439 of the epsilon heavy chain of IgE. A particularly preferred polypeptide competitor has a sequence of amino acids corresponding to amino acids 340 to 547 of the epsilon heavy chain of IgE as set out in Table V herein, which also shows the corresponding DNA sequence coding therefor. Such a polypeptide may also include additional short sequences at the beginning and/or end of the core sequence which are physiologically harmless and do not contribute to the ability of the core sequence to compete with native IgE for the low affinity receptor sites on human cells. The polypeptide may be produced synthetically or by expression from Escherichia coli containing a plasmid having a DNA segment coding for the polypeptide.Type: GrantFiled: May 31, 1995Date of Patent: December 2, 1997Assignee: 501 Research Corporation LimitedInventors: Hannah Jane Gould, Birgit Anna Helm, Philip John Henry Benedict Marsh
-
Patent number: 5691454Abstract: A human gene termed APC is disclosed. Methods and kits are provided for assessing mutations of the APC gene in human tissues and body samples. APC mutations are found in familial adenomatous polyposis patients as well as in sporadic colorectal cancer patients. APC is expressed in most normal tissues. These results suggest that APC is a tumor suppressor.Type: GrantFiled: May 25, 1995Date of Patent: November 25, 1997Assignees: The Johns Hopkins University, University of Utah, the Cancer Institute, Imperial Chemical Industries PLCInventors: Hans Albertsen, Rakesh Anand, Mary Carlson, Joanna Groden, Philip John Hedge, Geoff Joslyn, Kenneth Kinzler, Alexander Fred Markham, Yusuke Nakamura, Andrew Thliveris, Bert Vogelstein, Raymond L. White
-
Patent number: 5688681Abstract: The invention relates to monoclonal antibodies to human leukemia inhibitory factor. The disclosed monoclonal antibodies are believed to recognize unique epitopes on hLIF and are useful in the treatment of conditions wherein the presence of hLIF causes or contributes to undesirable pathological effects, such as cachexia, dysregulated calcium metabolism, or excessive bone cell proliferation, and in the detection of hLIF, for example, in clinical samples or specimens.Type: GrantFiled: June 13, 1994Date of Patent: November 18, 1997Assignee: Genentech, Inc.Inventor: Kyung Jin Kim
-
Patent number: 5688918Abstract: The invention comprises plasmids and viral vectors containing an animal p53as cDNA sequence. A portion of the p53as sequence may be identified to a position of wild type p53 gene from the same animal. In preferred embodiments, the p53as is mouse or human p53as. A preferred viral vector is baculovirus vector. The invention further includes antibodies both polyclonal and monoclonal, to p53as and to at least a portion of human p53 intron 10 sequence encoding SLRPFKALVREKGHRPSSHSC which is related to p53as sequences and plasmids and viral vectors containing such sequences. All of the above find utility in studying p53 and p53as and their relative expressions which is believed important for detection and control of malignant cells and their susceptibility to treatment agents.Type: GrantFiled: June 14, 1994Date of Patent: November 18, 1997Assignee: Health Research, Inc.Inventor: Molly F. Kulesz-Martin
-
Patent number: 5686292Abstract: Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treating cancer using the HGF receptor antagonists are also provided.Type: GrantFiled: June 2, 1995Date of Patent: November 11, 1997Assignee: Genentech, Inc.Inventors: Ralph H. Schwall, Kelly Helen Tabor
-
Patent number: 5684146Abstract: An isolated DNA is provided coding for the variable region of an anti-human influenza A type virus antibody having the following characteristics: (a) specifically binds to the stem region of haemaggulutinin molecule of H1N1 and H2N2 subtypes of human influenza A type virus but does not specifically bind to the stem region of haemaggulutinin molecule of H3N2 subtype; and (b) has a neutralization activity for the H1N1 and H2N2 subtypes of human influenza A type virus but no neutralization activity for the H3N2 subtype.Type: GrantFiled: March 10, 1995Date of Patent: November 4, 1997Assignee: Takara Shuzo Co., Ltd.Inventors: Yoshinobu Okuno, Atsushi Oshima, Hirofumi Yoshioka, Takashi Takabatake, Ikunoshin Kato
-
Patent number: 5681931Abstract: Human restrictin proteins and nucleic acid sequences encoding them are provided. Antibodies which recognize human restrictin in human brain are disclosed. In the human brain, restrictin occurs as two major polypeptides of 180 and 160 kD located in fiber tracts. These polypeptides are similar to those seen in rat brain. Surprisingly, restrictin has also been found in the peripheral nerves of rats and humans. The antibodies also detect a 170 kD polypeptide in MATRIGEL, an extracellular matrix product of rat EHS sarcoma cells widely used as a tissue culture substrate. Monoclonal antibodies to human restrictin and assays using the human restrictin protein, antibodies and DNA sequences are also provided.Type: GrantFiled: March 15, 1995Date of Patent: October 28, 1997Assignee: Becton, Dickinson and CompanyInventors: Robert Alan Reid, Rhonda Lucille Ackley, John Jacob Hemperly
-
Patent number: 5681923Abstract: The active, galactose binding site of proteins associated with metastatic tumor cells has been identified and sequenced (SEQ. ID. NO:1). The polypeptide comprising the active site may be used as an immunotherapeutic agent. Identification of the site makes possible an in vivo diagnostic assay for metastatic cells as well as therapeutic methodologies and materials.Type: GrantFiled: October 6, 1995Date of Patent: October 28, 1997Inventor: David Platt
-
Patent number: 5677181Abstract: Antibodies, including monoclonal antibodies, specific for proliferating/angiogenic human endothelial cells such as human umbilical vein endothelial cells and human umbilical artery endothelial cells, and conjugates of these antibodies with a toxin material or label, are useful for inhibition of angiogenesis or for treatment of angiogenesis-dependent disease.Type: GrantFiled: July 3, 1995Date of Patent: October 14, 1997Assignee: The Australian National UniversityInventor: Christopher Richard Parish
-
Patent number: 5672502Abstract: Process for the fed-batch culture of animal cells comprises culturing the cells in nutrient medium characterized in that during the culture the medium is supplemented with a combined feed of one or more energy sources and one or more animo acids, and culturing is continued into the decline phase of the culture to provide the product(s) of the cells. The process is particularly applicable to genetically modified cells, especially hybridoma cell cultures to produce monoclonal antibodies. Preferably, the supplemental feed is fed to the culture at a slow rate over a prolonged period. Very significant enhancement of overall product yield may be obtained.Type: GrantFiled: February 28, 1995Date of Patent: September 30, 1997Assignee: Celltech Therapeutics LimitedInventors: John Robert Birch, Robert Charles Boraston
-
Patent number: 5672686Abstract: The present invention is directed to an isolated Bcl-Y protein, nucleotide sequences coding for and regulating expression of the protein, antibodies directed against the protein, and recombinant vectors and host cells containing the genetic sequences coding for and regulating the expression of the protein sequence. The invention is also directed to genomic DNA, cDNA, and RNA encoding the Bcl-Y protein sequence and to corresponding antisense RNA sequences. Antibodies can be used to detect Bcl-Y in biological specimens, including, for example, human tissue samples. The present invention is further directed to methods of treating degenerative disorders characterized in inappropriate cell proliferation or inappropriate cell death. The present invention is further directed to methods for diagnosing degenerative disorders characterized in inappropriate cell proliferation or inappropriate cell death, as well as methods for monitoring the progress of such degenerative disorders.Type: GrantFiled: October 11, 1994Date of Patent: September 30, 1997Assignee: ImmunoGen, Inc.Inventor: Thomas D. Chittenden
-
Patent number: 5668003Abstract: The invention relates to nucelic acids encoding monoclonal antibodies to human leukemia inhibitory factor. The disclosed monoclonal antibodies are believed to recognize unique epitopes on hLIF and are useful in the treatment of conditions wherein the presence of hLIF causes or contributes to undesirable pathological effects, such as cachexia, dysregulated calcium metabolism, or excessive bone cell proliferation, and in the detection of hLIF, for example, in clinical samples or specimens.Type: GrantFiled: May 10, 1995Date of Patent: September 16, 1997Assignee: Genentech, Inc.Inventor: Kyung Jin Kim
-
Patent number: 5667780Abstract: Isolated SMDF, isolated DNA encoding SMDF, and antibodies to SMDF are disclosed. SMDF contains a .beta.-type EGF-like domain and a N-terminal sequence which is distinct from all neuregulins reported so far. SMDF, when expressed in recombinant cell culture, activates tyrosine phosphorylation of the HER2/neu receptor in human breast cancer cells and displays mitogenic activity on Schwann cells. Northern blot and in situ hybridization analysis show that SMDF differs from other neuregulins in that it is nervous tissue specific, and is very highly expressed, in comparison to other neuregulins, in the human and rat spinal cord motor neurons and sensory neurons.Type: GrantFiled: April 25, 1995Date of Patent: September 16, 1997Assignee: Genentech, Inc.Inventors: Wei-Hsien Ho, Phyllis L. Osheroff
-
Patent number: 5665866Abstract: This invention relates to a process for obtaining antibodies in soluble and correctly folded and assembled form. It comprises a step to raise the temperature at a time in the process selected to facilitate the subsequent isolation of soluble, correctly folded and assembled antibody, substantially free of other antibody-related material. The operating temperature may be raised at any stage in the microbial fermentation or eukaryotic cell culture, or at any stage during extraction and purification of the antibodies.Type: GrantFiled: March 14, 1995Date of Patent: September 9, 1997Assignee: Celltech Therapeutics LimitedInventors: Andrew Neil Charles Weir, Neil Andrew Bailey
-
Patent number: 5662904Abstract: A composition for use in the treatment of wounds to inhibit scar tissue formation during healing, comprising an effective amount of an activity-inhibiting growth factor neutralizing agent or agents specific against all TGF-.beta., except for TGF-.beta..sub.3, and PDGF, together with a pharmaceutically acceptable carrier. A method of preparing the composition and a method of administering the composition to a host suffering from tissue wounding is also disclosed.Type: GrantFiled: September 27, 1993Date of Patent: September 2, 1997Assignee: The Victoria University of ManchesterInventors: Mark William James Ferguson, David Michael Foreman, Mamta Shah
-
Patent number: 5662899Abstract: Macrophages have been developed, which possess at least one of the following properties:their cytotoxic activity without IFN-.gamma. is increased by about 20 to 30% with respect to standard macrophages, and is preferably of about 70%;their cytotoxic activity with IFN-.gamma. is increased by about 20 to about 40% with respect to standard macrophages, and is preferably of about 93%;deactivation of the cytotoxic activity following activation of IFN-.gamma. is such that sixty hours after activation with IFN-.gamma., the residual cytotoxic activity is at least 30%, preferably about 55%, of the maximum cytotoxic activity presented by the macrophages due to IFN-.gamma. activation, with said cytotoxic activity being measured as a percentage of the inhibition of 3-H thymidine incorporation by target tumoral cells, particularly U 937 cells. The macrophages are prepared by culturing healthy human monocytes and lymphocytes in a culture medium containing 1,25-dihydroxy vitamin D.sub.3 and GM-CSF.Type: GrantFiled: January 17, 1995Date of Patent: September 2, 1997Assignee: I.D.M. Immuno-Designed MoleculesInventors: Mohamed Chokri, Jacques Bartholeyns
-
Patent number: 5658791Abstract: The invention relates to antibodies which specifically bind to tyrosine kinase active proteins. The proteins have more than one protein kinase domain, and no SH2 domains. Exemplary proteins are the Janus Kinases, or "JAK1" and "JAK2". Both polyclonal and monoclonal antibodies are a part of the invention, as are hybridomas which produce the monoclonal antibodies.Type: GrantFiled: May 19, 1995Date of Patent: August 19, 1997Assignee: Ludwig Institute For Cancer ResearchInventors: Andrew Frederick Wilks, Andrew Ziemiecki, Ailsa Harpur
-
Patent number: 5654405Abstract: Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used successfully to produce hitherto unknown human keratinocyte growth factor (KGF) protein free of other polypeptides. These proteins can be produced in various functional forms from spontaneously secreting cells or from DNA segments introduced into cells. These forms variously enable biochemical and functional studies of this novel protein as well as production of antibodies. Means are described for determining the level of expression of genes for the KGF protein, for example, by measuring mRNA levels in cells or by measuring antigen secreted in extracellular or body fluids.Type: GrantFiled: May 31, 1995Date of Patent: August 5, 1997Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Jeffrey S. Rubin, Paul W. Finch, Stuart A. Aaronson